ARTICLE | Finance
Regulatory antibody strategy vs. allergies
June 21, 1993 7:00 AM UTC
Allergene Inc., which is developing regulatory antibodies to treat allergic diseases, told BioCentury that it is looking to raise a second venture round of about $5 million from either venture capital or private investors.
Allergene is about 18 months away from the clinic with antibodies to poison ivy/oak and grasses. The company is developing chimeric versions of antibodies it has tested in animals...